

Review of: "Enhancing Patient-Centric Approaches and Regulatory Measures in Valproate Use"

Giselle A. Borges e Soares¹

¹ University of Toledo

Potential competing interests: No potential competing interests to declare.

I do like how the abstract is worded. However, the scientific backing in the paper is lacking. I would prefer to have some studies on Valproate mentioned in the paper along with the findings. A table with dosages, routes of administration tested, species, etc., would make the data more coherent. Moreover, for people who are not familiar with valproate, mentioning the mechanism of action, providing its structure, and giving details on the pharmacokinetics/dynamics of the drug would be beneficial. The paper also specifies only MHRA; why is the USFDA not mentioned?